Meeting
2017 Gastrointestinal Cancers Symposium
Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
Authors
Mitsukuni Suenaga
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Mitsukuni Suenaga , Marta Schirripa , Shu Cao , Wu Zhang , Dongyun Yang , Federica Marmorino , Francesca Bergamo , Carlotta Antoniotti , Daniele Rossini , Yan Ning , Satoshi Okazaki , Martin D. Berger , Yuji Miyamoto , Roel Gopez Jr., Diana L. Hanna , Afsaneh Barzi , Tetsuo Mashima , Toshiharu Yamaguchi , Fotios Loupakis , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 596)
DOI
10.1200/JCO.2017.35.4_suppl.596
Abstract #
596
Poster Bd #
D14
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Gene polymorphisms of CCL3, CCL4, CCL5, and CCR5 network in metastatic colorectal cancer patients treated with regorafenib.
First Author: Mitsukuni Suenaga
Poster
2018 Gastrointestinal Cancers Symposium
Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2016 ASCO Annual Meeting
Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2017 ASCO Annual Meeting
Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.
First Author: Mitsukuni Suenaga